Liver

In preparation for the 2026 Banff Meeting to be held Oct 5-9, 2026 in Banff, Canada - we are soliciting input from the international transplant community on guiding the discussions at the in-person meeting. Please share your thoughts on the following questions to each of the sessions in your area of interest listed in the blog: (the full program and registration information for the 2026 Banff meeting can be found here: https://site.pheedloop.com/event/2026banffmeeting/schedule)*

*Some final changes to session and presentation titles might occur.    

What are the most important knowledge gaps and/or unmet clinical needs for this session?        

What questions would you ask the moderators and speakers at this session?       

Banff Liver Concurrent I

Results of Late TCMR Study for Banff Scoring

Predictive biomarkers of rejection in liver allografts

Molecular Associations of IH

Comparative spatial immunopathology of AMR, TCMR, plasma cell-rich hepatitis and idiopathic post-transplant hepatitis in liver allografts

Importance of DSA in Liver Transplant in 2026

Interplay of cells and antibodies in late allografts

What are the most important knowledge gaps and/or unmet clinical needs for this session?        

What questions would you ask the moderators and speakers at this session?

Banff Liver Molecular Workgroup: Molecular Tools in Kidney Allograft Rejection: Evidence to Date and Innovations on the Horizon

Introduction and status of molecular diagnostic tools in kidney allograftrejection

Head-to-Head Comparison of the MolecularMicroscope and the Banff B-HOT Panel in Kidney Allografts: Lessons for Application in Liver Transplantation

Molecular Diagnostics in Liver Allograft Rejection: What We Know and What’s Next

AMR/TCMR signatures

Identification of NK cell-rich rejection

Molecular signatures for less IST

Use of nCounter in native liver diseases

What are the most important knowledge gaps and/or unmet clinical needs for this session?        

What questions would you ask the moderators and speakers at this session?

Banff Liver Concurrent II:

Innovations in Late Transplant Management to achieve tolerance – lessons learned

Improving Liver Allograft Acceptance: The future and how to get there

Revised classification of TCMR and how late rejection likely involves a cooperation between cell and antibody-mediated injury

Pathology Framework for Immunosuppression Minimization

Proposal for Standardizing Clinicopathological and Serological Definition of Late Liver Allograft Rejection for Clinical Trials